NEW
YORK, Apr 25, 2024 /PRNewswire/ -- Lindus
Health, the "anti-CRO" running radically faster, more reliable
clinical trials for life science pioneers, has released a
comprehensive contract research organization (CRO) offering
tailor-made for sponsors looking to bring diagnostic products to
market.
Lindus Health has enrolled over 30,000 patients in diagnostic
trials to date across the US, UK, and Europe, and has consistently proven success in
running clinical trials across a variety of different diagnostic
products therapeutic areas spanning oncology, infectious disease,
respiratory, women's health, and more. With the introduction
of the "All-in-One Diagnostics CRO, Lindus will elevate its
diagnostics clinical trials by leveraging its expertise in the
testing, monitoring, and biomarker identification of indications
across nearly all therapeutic areas and addresses the challenges
associated with recruiting and managing data for very large patient
studies.
The new offering combines expert CRO services and extensive
experience in diagnostic clinical trials with their repository of
over 30 million electronic health records (EHRs) and home-grown
internal eClinical platform, Citrus™, to provide diagnostics
sponsors with everything they need to conduct research all in one
place.
Many diagnostics validation clinical trials require upwards of
tens of thousands of patients to be recruited in short periods of
time, which can be achieved with Lindus' new offering. Their
primary care and proprietary, specialty network databases, along
with in-house direct-to-patient marketing and remote participation
tools, helps sponsors recruit patients two times faster.
"Diagnostics studies have unique challenges that are poorly
served by traditional CROs, who approach these studies much like a
drug trial, and therefore fall short in delivering studies on time
and on budget," said Michael Young,
Co-Founder at Lindus Health. "These studies require specific
expertise in validating products against a standard of care and
also have very demanding and unique recruitment challenges with
some studies requiring thousands of patients. Most CROs don't know
how to handle studies at this scale except through, driving immense
cost and trial complexity."
Diagnostics sponsors can benefit from the following features as
part of the "All-in-One Diagnostics CRO" offering:
- CRO and trial management solutions: From protocol
development and patient recruitment through data delivery, Lindus
Health's clinical operations team possesses deep knowledge in all
facets of diagnostics clinical trials.
- Bespoke trial management technology: Citrus™,
Lindus Health's proprietary eClinical software tailored to each
study, houses all the necessary technologies needed for trial
execution, including the Clinical Trial Management System (CTMS),
Electronic Data Capture (EDC), eConsent, patient scheduling,
eConsent, and much more.
- Large-scale recruitment capabilities: A variety of
recruitment tactics are used to accelerate patient enrollment,
including Lindus Health's primary care network of over 30 million
EHRs and an in-house digital marketing team for social media
advertising campaigns.
- Expansive knowledge in diagnostics and regulatory
pathways: With a track record of submitting numerous trials for
FDA 510(k) and De Novo submissions, Lindus Health's expert
diagnostics team stays abreast of industry developments and is
experienced in regulatory submissions for diagnostics
products.
- Exceptional site services and network: Lindus Health's
dedicated site operations team fosters strong relationships with
principal investigators (PI) and research staff and effectively
carries out trials of various models, from single- to multi-site as
well as remote/hybrid and traditional settings. Sites are deployed
across the company's primary care and specialty care network
depending on the needs of the study population.
"With the appointment of Lindus Health, our US market access
program is well underway to achieve our goal of obtaining
regulatory approval for the initial pre-surgical market in the U.S.
for our ovarian cancer blood test," said Richard Allman, CEO of CLEO Diagnostics, an
ovarian cancer diagnostics company. "We are appointing high-caliber
partners that we believe will help us deliver important ovarian
cancer detection technology to improve the health outcomes for
women."
Lindus Health's roster of diagnostics expertise extends to its
advisory board, including Bob
Langer, co-founder at Moderna and institute professor at
MIT and Alessandro Falcone, Executive Director of Breast
Cancer Oncology R&D Strategy at AstraZeneca.
Lindus Health is devoted to pioneering exceptional diagnostics
research, offering efficiency and versatility to provide
exceptional clinical trial experiences for both sponsors and
patients.
To learn more about Lindus Health's "All-in-One Diagnostics
CRO", click here.
About Lindus Health
Lindus Health is an anti-CRO running radically faster and more
reliable trials for life science pioneers – bringing
ground-breaking treatments to patients more quickly. Lindus
Health does this thanks to a commercial model that aligns
incentives (fixed-priced quotes per study, with milestone-based
payments), marrying a world-class clinical operations team with its
unique software platform, and access to 30 million Electronic
Health Records. Clinical trials are the biggest bottleneck to
advances in healthcare and by removing this constraint they aim to
improve health for everyone. They handle the end-to-end execution
of clinical studies, including design, patient recruitment,
clinical data capture, monitoring and project management.
To date, Lindus Health has delivered more than 90 trials across
the US, UK and Europe to tackle a
range of conditions including diabetes, asthma, acne, social
anxiety, major depressive disorder, hypertension, chronic fatigue
syndrome and insomnia.
The company was named after James
Lind, who pioneered the first clinical trial and treatment
for scurvy, and co-founded by Michael
Young, a former Special Adviser to the UK Prime Minister on
Life Sciences, and Meri Beckwith, a
former life sciences investor.
Lindus Health has raised over $24M
from investors including Peter
Thiel, CREANDUM, Firstminute Capital, Presight Capital,
Seedcamp, Hambro Perks, Amino Collective and Calm/Storm.
Press Contact:
Jodi
Perkins
Amendola Communications
JPerkins@acmarketigpr.com
847-508-0877
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lindus-health-debuts-all-in-one-diagnostics-cro-solution-for-diagnostic-clinical-trials-302126728.html
SOURCE Lindus Health